Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority TrialVanita Noronha, Kumar Prabhash, Prathamesh Pai et al.|Journal of Clinical Oncology|2017Cited by 340
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancerVijay Patil, Manish Pandey, Vanita Noronha et al.|Cancer|2019Cited by 133
Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.Vijay Patil, Kumar Prabhash, Vanita Noronha et al.|Journal of Clinical Oncology|2018Cited by 11
Under-representation of older Indian persons with cancer in clinical trialsVanita Noronha, Kumar Prabhash, Vijay Patil et al.|BMJ Oncology|2024Cited by 5
Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma.Vanita Noronha, Kumar Prabhash, Vijay Patil et al.|Journal of Clinical Oncology|2022Cited by 3